Dr. Jessica Hopfield Appointed to Berkeley Lights Board of Directors
Addition of Experienced Independent Director with Accomplished Business Record Underscores Berkeley Lights Board of Directors’ Commitment to Delivering Value for...
News
Neuronetics Announces 510(k) Clearance of MT Cap Technology for NeuroStar® Advanced Therapy for Mental Health
Technology will save practitioners and patients time during motor threshold determinationMALVERN, Pa., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc....
Bioventus Receives US FDA Clearance for BoneScalpel® Access™
DURHAM, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in...
BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients
A novel first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for more than 45% of commercially insured patients in...
Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline...
CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company...
ALR Technologies Releases an Open Letter to Shareholders
SINGAPORE, Dec. 20, 2021 (GLOBE NEWSWIRE) -- ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today...
Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics today announces the appointments of Dr. Stephen Wright and Dr....
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada Lugano, Switzerland, and Mississauga, Ontario, 20...
Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada
Treatment for Hepatitis C Virus (HCV) is effective in over 95% of infected patients, yet remains disproportionately unavailable to certain...
FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment,...
Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH
Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the yearNEW YORK, Dec. 20, 2021...
Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease...
Turning Point Therapeutics Provides Regulatory Updates
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation...
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell...
Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022
Company has enrolled 10 of the targeted 16 patients in the trial Anticipates interim data in mid-2022 and topline data...
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved...
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Company retains iiiNTENT SAAS artificial intelligence marketing service for Tollovid® and Tollovid Daily™ 3CL protease inhibitor dietary supplement products NEW...
Avicanna and Harrington Wellness launch re+PLAY™ branded CBD topicals products in Canada
re+PLAY(TM) re+PLAY(TM) - a Harrington Wellness product re+PLAY is a sports performance and recovery-focused brand founded by NBA veteran Al...
KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
CELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and...
